---
title: 'Associate Director, Clinical Data Management at Remix Therapeutics'
canonical: 'https://feeny.ai/job/associate-director-clinical-data-management-remix-therapeutics-watertown-qq070g410ywh'
type: 'job'
last_seen: '2026-10-24'
---

# Associate Director, Clinical Data Management at Remix Therapeutics

- **Company:** Remix Therapeutics
- **Location:** Watertown, MA
- **Posted:** 2026-10-02
- **Last confirmed live:** 2026-10-24
- **Apply:** https://job-boards.greenhouse.io/remixtherapeutics/jobs/4740128005

## Job description

Remix Therapeutics is a clinical-stage biopharmaceutical company that has pioneered a new class of small molecule medicines targeting the RNA splicing machinery — correcting the disease-causing errors that drive cancers and other serious conditions at their source.

REM-422 is our lead program currently focused on developing a therapy for Adenoid Cystic Carcinoma (ACC), a rare cancer for which there is no approved therapy. REM-422 is concurrently being evaluated as a treatment for AML/.HR-MDS with aspirations to evolve into other oncology indications with high unmet need. REM-422 is at a critical inflection point in its clinical development and Remix is building the team to bring this novel molecule forward as a medicine for patients.

Position Summary:

Remix is seeking an Associate Director, Clinical Data Management to provide technical expertise and vendor oversight at a pivotal moment for REM-422 and the ACC patients we serve. Reporting to the SVP, Clinical Development Operations & Patient Advocacy and based at our Watertown, MA headquarters, this role is the first to be solely dedicated to the Clinical Data Management function. Accordingly, the role will be responsible for developing and executing Remix standards and processes tailored to the oversight of outsourced solutions suitable for Registration programs as well as early development programs to follow.

This is a locally based position, and we are only considering candidates who currently reside within commuting distance of our Watertown, MA headquarters.

Key Responsibilities:

CRO & Vendor Management

- Oversight & Accountability: Manage and provide robust operational oversight of functional deliverables from data management CROs and specialized vendors (e.g., central labs, ePRO, IRT).
- Governance & Metrics: Establish and monitor CRO performance metrics, Key Performance Indicators (KPIs), and quality metrics. Lead routine governance and alignment meetings to track study progress and resolve data issues.
- Financial Control: Participate in CRO selection, Request for Proposal (RFP) evaluations, and bid defense meetings. Review and manage the DM vendor budget, including the evaluation of Statements of Work (SoW) and potential Change Orders.
- Deliverable Approval: Critically review and approve core vendor deliverables, including Data Management Plans (DMPs), Case Report Form (eCRF) designs, Edit Check Specifications, User Acceptance Testing (UAT) setups, and Data Transfer Specifications.

Data Management Operations & Quality Assurance

- Trial Lifecycle Leadership: Lead data management activities from initial protocol review and study start-up through database cleaning, lock, and archival.
- Data Integrity & Review: Conduct ongoing data reviews via data listings and visualization tools to identify data anomalies, trends, and systemic risks across clinical programs.
- Compliance & Inspection Readiness: Ensure all data operations strictly adhere to ICH-GCP guidelines, corporate SOPs, and regulatory expectations. Serve as the Data Management Subject Matter Expert (SME) during internal audits and Health Authority inspections.
- Standardization: Collaborate on the design and maintenance of corporate data standards (e.g., CDISC/CDASH) to ensure downstream compatibility for biostatistics and electronic submissions.

Cross-Functional Leadership

- Study Team Representation: Serve as the primary Data Management representative on Trial Management Teams.
- Stakeholder Alignment: Actively partner with Biostatistics, Statistical Programming, Clinical Operations, Medical Writing, and Regulatory Affairs to ensure data management timelines align seamlessly with broader corporate objectives.

Qualifications:

- Education: BS/BA in a scientific, informatics, or healthcare discipline (Master’s or Ph.D. preferred).
- A minimum of 8+ years of experience in clinical drug development directly focused on Clinical Data Management within a pharmaceutical, biotech, or CRO environment.
- Deep expertise in industry-standard Electronic Data Capture (EDC) systems (e.g., Medidata Rave, Veeva Vault CDMS).
- Advanced knowledge of global regulatory frameworks, including ICH-GCP, FDA guidelines, EMA requirements, and CDISC standards.
- Proven track record of successfully managing full-service data management CROs and external vendors for complex or multi-center clinical trials.
- Deep oncology or rare disease trial experience preferred.
- Experience supporting clinical programs from IND through NDA submission and regulatory approval, including registrational trials and Inspection Readiness.
- Operates well in ambiguity; makes sound decisions with incomplete information; moves quickly without cutting corners and brings the team with them.

Salary Range:

$187,000 - $230,000 USD

This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable.  Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.

## About Remix Therapeutics

## Company Overview
- **One-liner**: Clinical-stage biotechnology company developing first-in-class oral small molecule therapies that reprogram RNA processing to address previously undruggable drivers of cancer and other diseases.
- **Entity Type**: Private (Venture-backed; merged with Passage Bio in June 2026 with a concurrent $100M private placement)
- **Headquarters**: Watertown, Massachusetts, United States
- **Founded**: 2018
- **Founders**: Peter Smith, PhD

## Core Business
- **Primary industry**: Biotechnology – RNA-targeted therapeutics, oncology
- **Target customers**: B2B (pharmaceutical partners like Roche and Johnson & Johnson) and B2C (patients with high-unmet-need cancers, served through healthcare providers)
- **Mission or purpose statement**: “Reprogramming RNA to transform patients’ lives” – focused on modulating RNA processing to address disease drivers at their origin

## Products & Services
- **REM‑422**: First-in-class, orally available small molecule mRNA degrader targeting the historically undruggable transcription factor MYB. Currently in Phase 1 clinical trials for acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR‑MDS), and adenoid cystic carcinoma (ACC). Granted FDA Fast Track designation for ACC.
- **REMaster™ Drug Discovery Platform**: Proprietary platform that designs small molecules to harness cellular RNA‑processing machinery, enabling modulation of gene expression for targets previously considered intractable. Used for internal pipeline and partnered programs.

## Market Standing
- **Valuation/Market Cap**: Not publicly disclosed (private company; post-merger valuation unknown)
- **Key Metric**: Total funding ~$240.7M (including a $100M private placement concurrent with the Passage Bio merger in June 2026). Annual revenue (2025 estimate): $3.2M (typical for a clinical‑stage biotech).
- **Notable Investors/Partners**:  
  - Investors: Surveyor Capital (Series B lead, $70M), Foresite Capital (Series A lead, $65M), The Column Group (Venture Round lead, $60M)  
  - Partners: Roche (collaboration for RNA‑processing modulators), Johnson & Johnson Innovative Medicine (multi‑year, three‑target oncology/immunology collaboration)  
- **Growth Signals**:  
  - Preliminary Phase 1 data for REM‑422 showed strong anti‑tumor activity and favorable safety in ACC  
  - FDA Fast Track designation for REM‑422 in ACC  
  - Merger with Passage Bio (June 2026) brings additional capital and pipeline synergies  
  - Active job postings up 200% month‑over‑month and quarter‑over‑quarter  
  - Headcount of 49 employees with a heavy concentration in research (43%)

## Competitive Advantages
- **Proprietary REMaster platform** uniquely enables oral small‑molecule modulation of RNA processing, expanding the druggable target space beyond traditional protein inhibition
- **First‑in‑class oral MYB mRNA degrader** (REM‑422) addresses a transcription factor long considered undruggable
- **Top‑tier pharma collaborations** with Roche and J&J validate the technology and provide non‑dilutive funding
- **Strong scientific leadership** (CEO/co‑founder Peter Smith, PhD, formerly CSO at H3 Biomedicine, where he advanced three molecules to the clinic)

## Strategic Focus
- Advance REM‑422 through Phase 1 trials across multiple MYB‑driven cancers (AML, HR‑MDS, ACC) and expand into additional solid tumors
- Leverage the REMaster platform to discover new RNA‑processing modulators for oncology and immunology
- Deepen existing pharma partnerships and seek new collaborations to accelerate pipeline growth
- Integrate the recently merged Passage Bio assets and utilize the $100M private placement to fund clinical development

## Why Work Here
- **Culture**: Values-driven environment centered on “True to Our RNA” (scientific integrity), “Courageous Curiosity” (bold innovation), and “Remixing Together” (collaboration and mutual support). Employees describe a flat, science‑first culture where diverse perspectives are welcomed.
- **Work model**: Hybrid? While not explicitly stated, the company has three offices in the Boston area (Watertown HQ, One Kendall Square Cambridge, and another Cambridge location). Lab‑based roles are likely on‑site; corporate roles may offer flexibility.
- **Perks & environment**: Small company (~49 people) with the energy of a startup but backed by significant funding and pharma partnerships. Employees share a strong sense of mission to bring new therapies to patients with few options. “We take our work seriously but not ourselves.”
- **Growth opportunity**: Rapidly advancing clinical pipeline and post‑merger expansion offer career advancement in a high‑visibility biotech. Recent ramp‑up in hiring (3 active postings for senior leadership roles like VP of Program Team Lead, VP of Biostatistics, and Senior Manager of Strategy & BD) signals scaling.

## Sources
1. [Remix Therapeutics Home](https://www.remixtx.com/)
2. [Remix Therapeutics About Us](https://www.remixtx.com/about/)
3. [Remix Therapeutics Join Us](https://www.remixtx.com/join/)
4. [Remix Therapeutics LinkedIn](https://www.linkedin.com/company/remix-therapeutics)
5. [Remix Therapeutics Greenhouse Careers](https://job-boards.greenhouse.io/remixtherapeutics)

## Other roles at Remix Therapeutics

- [Senior Director, GCP Quality](https://feeny.ai/job/senior-director-gcp-quality-remix-therapeutics-watertown-ancn66bxrnf3) — Watertown, MA
- [Head of Medical Affairs](https://feeny.ai/job/head-of-medical-affairs-remix-therapeutics-watertown-x0b0ddpp9nnc) — Watertown, MA
- [Vice President/Senior Director, Nonclinical Drug Safety & Toxicology](https://feeny.ai/job/vice-president-senior-director-nonclinical-drug-safety-toxicology-remix-hcv58wta0q0b) — Watertown, MA
- [Vice President, Clinical Development](https://feeny.ai/job/vice-president-clinical-development-remix-therapeutics-watertown-0ewyfa0bvx9g) — Watertown, MA
- [Associate Director, Clinical Data Management](https://feeny.ai/job/associate-director-clinical-data-management-summit-therapeutics-palo-alto-ajbgvdjdda9f) — Palo Alto, CA
- [Associate Director, Clinical Data Management](https://feeny.ai/job/associate-director-clinical-data-management-eikon-therapeutics-jersey-city-6rkwk4ya8pa0) — Jersey City, NJ / Millbrae, CA